


Bijlage Subgroup analyses per atypical antipsychotic for the crucial outcome measures

1.1 Subquestion - placebo

1. Psychosis

Figure S1. Psychosis: Forest plot of the SMD on the effect of atypical antipsychotics versus placebo, with subgroups per atypical antipsychotic



Test for subgroup differences: Chi² = 1.67, df = 4 (P = 0.80), I² = 0%

¹ Deberdt (2005) F1D MC HGGU: Olanzapine (2.5-10 mg/day)

² De Deyn (2004) F1D MC HGIV: Olanzapine (1.0, 2.5, 5.0, or 7.5 mg/day)

³ Deberdt (2005) F1D MC HGGU: risperidone (0.5-2 mg/day)

⁴ Mintzer (2006) RIS USA 232: risperidone (1.0-1.5 mg/day)

⁵ NCT00287742 (2006): risperidone (0.5-2 mg/day)

⁶ RIS-INT-83 (2003): risperidone (1-1.5 mg/day)

⁷ Schneider (2003) RIS USA 63: risperidone (1, 2, or 4 mg/day)

⁸ Ballard (2018): Pimavanserin (2x17 mg tablets daily)

⁹ De Deyn (2005): Aripiprazole (2-15 mg/day)

¹⁰ Mintzer (2007): Aripiprazole (2, 5, or 10 mg/day)


¹¹ Streim (2008): Aripiprazole (2-15 mg/day)

¹² Paleacu (2008): Quetiapine (50-300 mg/day)

¹³ Tariot (2006): Quetiapine (25-600 mg/day)

2. Somnolence

Figure S2. Somnolence: Forest plot of the risk ratio on the effect of atypical antipsychotics versus placebo, with subgroups per atypical antipsychotic.



¹ Deberdt (2005) F1D MC HGGU: Olanzapine (2.5-10 mg/day)

² Schneider (2006): Olanzapine (tablets of 2.5 and 5.0 mg. Mean last dose 5.5 mg/day)

³ Brodaty (2003) RIS-AUS-05: risperidone (0.5-2 mg/day)

⁴ Deberdt (2005) F1D MC HGGU: risperidone (0.5-2 mg/day)

⁵ Mintzer (2006) RIS USA 232: risperidone (1.0-1.5 mg/day)

⁶ Schneider (2006): risperidone (tablets of 0.5 and 1.0 mg. Mean last dose 1.0 mg/day)

⁷ Ballard (2018): Pimavanserin (2x17 mg tablets daily)

⁸ De Deyn (2005): Aripiprazole (2-15 mg/day)

⁹ Mintzer (2007): Aripiprazole (2, 5, or 10 mg/day)

¹⁰ Streim (2008): Aripiprazole (2-15 mg/day)

¹¹ Paleacu (2008): Quetiapine (50-300 mg/day)

¹² Schneider (2006): Quetiapine (tables of 25 and 50 mg. Mean last dose 56.6 mg/day)

¹³ Tariot (2006): Quetiapine (25-600 mg/day)


¹⁴ Zhong (2007): Quetiapine (100-200 mg/day)

¹⁵ Allain (2000): Tiapride (100 mg/day; dose could be progressively increased to a maximum of 300 mg/day)

¹⁶ Grossberg (2020b): Brexpiprazole (0.5-2 mg/day)

3. Extrapyramidal symptoms

Figure S3. Extrapyramidal symptoms: Forest plot of the risk ratio on the effect of atypical antipsychotics versus placebo, with subgroups per atypical antipsychotic.



- ¹ Deberdt (2005) F1D MC HGGU: Olanzapine (2.5-10 mg/day)
- ² Schneider (2006): Olanzapine (tablets of 2.5 and 5.0 mg. Mean last dose 5.5 mg/day)
- ³ Brodaty (2003) RIS-AUS-05: risperidone (0.5-2 mg/day)
- ⁴ Deberdt (2005) F1D MC HGGU: risperidone (0.5-2 mg/day)
- ⁵ Mintzer (2006) RIS USA 232: risperidone (1.0-1.5 mg/day)
- ⁶ NCT00287742 (2006): risperidone (0.5-2 mg/day)
- ⁷ RIS-INT-83 (2003): risperidone (1-1.5 mg/day)
- ⁸ Schneider (2006): risperidone (tablets of 0.5 and 1.0 mg. Mean last dose 1.0 mg/day)
- ⁹ De Deyn (2005): Aripiprazole (2-15 mg/day)
- ¹⁰ Mintzer (2007): Aripiprazole (2, 5, or 10 mg/day)
- ¹¹ Streim (2008): Aripiprazole (2-15 mg/day)
- ¹² Paleacu (2008): Quetiapine (50-300 mg/day)
- ¹³ Schneider (2006): Quetiapine (tables of 25 and 50 mg. Mean last dose 56.6 mg/day)
- ¹⁴ Tariot (2006): Quetiapine (25-600 mg/day)
- ¹⁵ Zhong (2007): Quetiapine (100-200 mg/day)

¹⁶ *Allain (2000): Tiapride (100 mg/day; dose could be progressively increased to a maximum of 300 mg/day)*

¹⁷ *Grossberg (2020a): Brexpiprazole (0.5-2 mg/day)*

¹⁸ *Grossberg (2020b): Brexpiprazole (0.5-2 mg/day)*